Clinical Trial Update: Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma [Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 2 study evaluating Avastin (bevacizumab) plus the GemAOD regimen as first-line therapy for Extranodal NK/T-cell lymphoma, nasal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• Avastin (bevacizumab)
• GemAOD

Snippet

Sponsor: Sun Yat-sen University | Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type | Phase 2 | Status: UNKNOWN